CD103 and periplakin are potential biomarkers for response of metastatic melanoma to pembrolizumab.

ABSTRACT: This study was designed to screen for preliminary evidence of predictive markers of melanoma response to PD-1 blockade. We hypothesized that the following immune markers would be positive predictors of response: increased densities of CD103 + CD8 + T cells or Th1 lineage T-bet + T cells, high expression of CXCL9-11 and presence of tertiary lymphoid structures. Conversely, we hypothesized that the high expression of barrier molecules would be a negative predictor of response. Patients with advanced melanoma treated with pembrolizumab were identified, and clinical response as well as overall survival data were collected. Tumor samples were evaluated by multiplex immunofluorescence histology. All statistical analyses were performed in R Studio and Microsoft Excel using the Mann-Whitney U test

SUBMITTER: Edmonds NL 

PROVIDER: S-EPMC9633418 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature